← Back to Clinical Trials
Recruiting NCT07184957

NCT07184957 Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07184957
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Prostate Cancer
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2017-05-01
Primary Completion 2030-12-31

Eligibility & Interventions

Sex Male only
Min Age 40 Years
Max Age 85 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2017-05-01 with a primary completion date of 2030-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This will be a prospectively maintained research database. The purpose is to record baseline parameters and treatment outcomes following of Cryotherapy for ablation of clinically localized prostate cancer.

Eligibility Criteria

Inclusion Criteria: * Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy * Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) will be counseled regarding treatment options. Those selecting focal Cryo prostate ablation will then be offered inclusion into this data collection. Exclusion Criteria: * Men that are not diagnosed with prostate cancer. * Men that are diagnosed with clinically localized prostate cancer, but select other treatment options as their desired treatment.

Contact & Investigator

Central Contact

Majlinda Tafa

✉ Majlinda.Tafa@nyulangone.org

📞 (646) 825-6338

Principal Investigator

James Wysock, MD

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT07184957 clinical trial?

This trial is open to male participants only, aged 40 Years or older, up to 85 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07184957 currently recruiting?

Yes, NCT07184957 is actively recruiting participants. Contact the research team at Majlinda.Tafa@nyulangone.org for enrollment information.

Where is the NCT07184957 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT07184957 clinical trial?

NCT07184957 is sponsored by NYU Langone Health. The principal investigator is James Wysock, MD at NYU Langone Health. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology